Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Ramirez-Martinez A, Wesolek N, Yadan JC, et al
A., Lam, M., Allen, B., Shariff, S
Are C, Humera R, Advaitaa C et al (2017) Global epidemiological trends and variations in the burden of gallbladder cancer
In rat studies, BPC-157 demonstrated healing effects in various colitis models, including cysteamine-induced colitis, improved intestinal anastomosis healing, and promoted closure of gastrointestinal fistulascomplications relevant to Crohn's disease.[4][5][3] The proposed mechanisms include interaction with the nitric oxide system, angiogenic effects, endothelium protection, and modulation of growth factor expression.[1][6] Critical limitations include the lack of published results from controlled human trials, absence of FDA approval, and concerns about products being sold online without regulatory oversight.[2] The peptide was temporarily banned by the World Anti-Doping Agency in 2022, though it is not currently listed as banned.[2] Given these limitations, BPC-157 cannot be recommended as standard therapy for ulcerative colitis or Crohn's disease based on current evidence
US$ 24.28
US$ 24.48
US$ 25.59
US$ 29.11
US$ 26.27
US$ 24.26
US$ 22.95
US$ 22.31
US$ 25.12
US$ 25.65